Autologous tumor neoantigens (polyclonal, patient-specific) drugs for Non-Small Cell Lung Cancer
2 tracked Autologous tumor neoantigens (polyclonal, patient-specific) drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the Autologous tumor neoantigens (polyclonal, patient-specific) page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 21 Phase 1
The roster
← all Autologous tumor neoantigens (polyclonal, patient-specific) drugs